Training the heart to calm the brain: a new hope for functional neurological disorders?

NCT ID NCT06422819

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial tests whether heart rate variability biofeedback—a non-invasive technique that teaches people to control their heart rhythm—can ease symptoms of functional neurological disorders (FND), a condition where the brain and nervous system don't function properly despite no structural damage. About 31 adults with a confirmed FND diagnosis will be trained in this technique and compared to a placebo group. The study measures changes in symptom severity, quality of life, and daily functioning to see if this mind-body approach offers a new, drug-free treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Heart rate variability biofeedback (HRV-BFB), a non-invasive technique that uses real-time heart rate feedback to help people learn to control unconscious bodily processes and regulate the autonomic nervous system.
What this could lead to
If effective, HRV biofeedback could offer a drug-free, non-invasive way to reduce symptoms and improve quality of life for people with functional neurological disorders.
What could go wrong
This is a small early-stage trial, and the placebo effect can be strong with biofeedback. It is unclear whether benefits will last or apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FUNCTIONAL NEUROLOGICAL DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Université de Montréal's affiliated Hospital Research Centre (CRCHUM)

    Montreal, Quebec, H2X 0C1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.